- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Pay-for-Delay Settlements
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, considers whether a recent law could help biosimilars.
Transcript
According to a recent law, the Federal Trade Commission and Department of Justice will review possible pay-for-delay settlements. Will this help biosimilars?
So I believe the act that the president passed in relation to getting information about settlements in the biologics space is in, I believe, the Collins act, and I think it will allow the Federal Trade Commission, the FTC, to at least start getting those documents and those agreements and making sense of if there is anti-competitive behavior that is happening.
We believe that is an important step—long overdue considering the Biologics Price Competition and Innovation Act has been around since 2009. This has existed in the small-molecule space under Hatch-Waxman that the FTC is entitled to get all of these documents.
So I think it’s a positive step, so the question remains whether the FTC has the ability and the powers too really enforce some of the anti-trust options that it might have. Unfortunately, companies have become very good at redefining what is a pay-for-delay settlement, they offer different incentives to the biosimilars companies, and those are not really fitting in the normal standard pay-for-delay descriptions that the Supreme Court has warned against in 2013 I believe.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
